非结核分枝杆菌肺病治疗的新见解 - Suppr

Suppr

超能文献

New insights in the treatment of nontuberculous mycobacterial pulmonary disease.

作者信息

Ruth Mike Marvin, van Ingen Jakko

机构信息

Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.

出版信息

Future Microbiol. 2017 Oct;12:1109-1112. doi: 10.2217/fmb-2017-0144. Epub 2017 Sep 20.

DOI:10.2217/fmb-2017-0144

PMID:28972416

Abstract

摘要

相似文献

New insights in the treatment of nontuberculous mycobacterial pulmonary disease.

Future Microbiol. 2017 Oct;12:1109-1112. doi: 10.2217/fmb-2017-0144. Epub 2017 Sep 20.

Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection.

Chest. 2017 Oct;152(4):800-809. doi: 10.1016/j.chest.2017.04.175. Epub 2017 May 5.

First pulmonary case reported in Argentina of infection with mycobacterium szulgai, a rare pathogen.

J Clin Microbiol. 2007 Sep;45(9):3121-4. doi: 10.1128/JCM.00148-07. Epub 2007 Jun 27.

Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches.

Expert Rev Respir Med. 2019 Sep;13(9):851-861. doi: 10.1080/17476348.2019.1638765. Epub 2019 Jul 8.

Medications and monitoring in nontuberculous mycobacteria infections.

Clin Chest Med. 2015 Mar;36(1):55-66. doi: 10.1016/j.ccm.2014.11.001. Epub 2014 Dec 18.

Activity of Clofazimine against Nontuberculous Mycobacteria Isolated in Beijing, China.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00072-18. Print 2018 Jul.

Management of nontuberculous mycobacterial (NTM) lung disease.

Semin Respir Crit Care Med. 2013 Feb;34(1):135-42. doi: 10.1055/s-0033-1333575. Epub 2013 Mar 4.

Skin disease and nontuberculous atypical mycobacteria.

Int J Dermatol. 2000 Sep;39(9):659-66. doi: 10.1046/j.1365-4362.2000.00821.x.

Introducing the new BTS Guideline: Management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).

Thorax. 2017 Nov;72(11):969-970. doi: 10.1136/thoraxjnl-2017-210929.

Antibiotic treatment for nontuberculous mycobacterial lung disease.

Expert Rev Respir Med. 2016;10(5):557-68. doi: 10.1586/17476348.2016.1165611. Epub 2016 Mar 30.

引用本文的文献

The Benzimidazole SPR719 Shows Promising Concentration-Dependent Activity and Synergy against Nontuberculous Mycobacteria.

Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02469-20.

Auranofin Activity Exposes Thioredoxin Reductase as a Viable Drug Target in .

Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00449-19. Print 2019 Sep.

Strong increase of true and false positive mycobacterial cultures sent to the National Reference Centre in Belgium, 2007 to 2016.

Euro Surveill. 2019 Mar;24(11). doi: 10.2807/1560-7917.ES.2019.24.11.1800205.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

New insights in the treatment of nontuberculous mycobacterial pulmonary disease.

Future Microbiol. 2017 Oct;12:1109-1112. doi: 10.2217/fmb-2017-0144. Epub 2017 Sep 20.

Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection.

Chest. 2017 Oct;152(4):800-809. doi: 10.1016/j.chest.2017.04.175. Epub 2017 May 5.

First pulmonary case reported in Argentina of infection with mycobacterium szulgai, a rare pathogen.

J Clin Microbiol. 2007 Sep;45(9):3121-4. doi: 10.1128/JCM.00148-07. Epub 2007 Jun 27.

Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches.

Expert Rev Respir Med. 2019 Sep;13(9):851-861. doi: 10.1080/17476348.2019.1638765. Epub 2019 Jul 8.

Medications and monitoring in nontuberculous mycobacteria infections.

Clin Chest Med. 2015 Mar;36(1):55-66. doi: 10.1016/j.ccm.2014.11.001. Epub 2014 Dec 18.

Activity of Clofazimine against Nontuberculous Mycobacteria Isolated in Beijing, China.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00072-18. Print 2018 Jul.

Management of nontuberculous mycobacterial (NTM) lung disease.

Semin Respir Crit Care Med. 2013 Feb;34(1):135-42. doi: 10.1055/s-0033-1333575. Epub 2013 Mar 4.

Skin disease and nontuberculous atypical mycobacteria.

Int J Dermatol. 2000 Sep;39(9):659-66. doi: 10.1046/j.1365-4362.2000.00821.x.

Introducing the new BTS Guideline: Management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).

Thorax. 2017 Nov;72(11):969-970. doi: 10.1136/thoraxjnl-2017-210929.

Antibiotic treatment for nontuberculous mycobacterial lung disease.

Expert Rev Respir Med. 2016;10(5):557-68. doi: 10.1586/17476348.2016.1165611. Epub 2016 Mar 30.

引用本文的文献

The Benzimidazole SPR719 Shows Promising Concentration-Dependent Activity and Synergy against Nontuberculous Mycobacteria.

Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02469-20.

Auranofin Activity Exposes Thioredoxin Reductase as a Viable Drug Target in .

Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00449-19. Print 2019 Sep.

Strong increase of true and false positive mycobacterial cultures sent to the National Reference Centre in Belgium, 2007 to 2016.

Euro Surveill. 2019 Mar;24(11). doi: 10.2807/1560-7917.ES.2019.24.11.1800205.